Exagen Inc. (XGN)
Stock Price:
$12.75 USD
0.04 (0.31%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
161.16M |
| Revenue (ttm) |
40.71M |
| Net Income (ttm) |
n/a |
| Shares Out |
12.64M |
| EPS (ttm) |
-72.27 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 2, 2020 |
| Last Price |
$12.75 |
| Previous Close |
$12.71 |
| Change ($) |
0.04 |
| Change (%) |
0.31% |
| Day's Open |
13.07 |
| Day's Range |
12.53 - 13.10 |
| Day's Volume |
32,331 |
| 52-Week Range |
10.29 - 29.86 |
More Stats
| Market Cap |
161.16M |
| Enterprise Value |
118.56M |
| Earnings Date (est) |
Nov 17, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
12.64M |
| Float |
2.67M |
| EPS (basic) |
n/a |
| EPS (diluted) |
-72.27 |
| FCF / Share |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
111,962 |
| Short Ratio |
4.18 |
| Short % of Float |
2.14% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
3.96 |
| PB Ratio |
2.92 |
| Revenue |
40.71M |
| Operating Income |
n/a |
| Net Income |
n/a |
| Free Cash Flow |
n/a |
| Net Cash |
42.60M |
| Net Cash / Share |
3.37 |
| Gross Margin |
53.01% |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-13.43% |
| ROE |
-65.76% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$18.50*
(45.10% upside)
Low
17.0
Current: 12.75
High
20.0
Target: 18.50
*Average 12-month price target from 2 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 |
|---|
| Revenue | 40.39 | 32.44 | 26.81 |
| Revenue Growth | 24.5% | 21.01% | - |
| Gross Profit | 21.58 | 17.06 | 12.67 |
| Operating Income | -9.30 | -4.88 | -7.89 |
| Net Income | -12.04 | -8.01 | -25.63 |
| Shares Outstanding | 3.58 | 0.06 | 0.06 |
| Earnings Per Share | -8.46 | -293.34 | -520.18 |
| Operating Cash Flow | -9.71 | -9.30 | -10.97 |
| Capital Expenditures | -0.10 | -0.20 | -0.51 |
| Free Cash Flow | -9.81 | -9.50 | -11.48 |
| Cash & Equivalents | 72.08 | 13.16 | 11.24 |
| Total Debt | 25.85 | 24.62 | 18.81 |
| Net Cash / Debt | 46.23 | -11.45 | -7.57 |
| Assets | 88.31 | 28.89 | 20.39 |
| Liabilities | 32.65 | 35.62 | 25.03 |
| Book Value | 55.66 | -112 | -96.68 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Exagen Inc. |
| Country |
United States |
| Employees |
153 |
| CEO |
Fortunato Ron Rocca |
Stock Information
| Ticker Symbol |
XGN |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Diagnostics & Research |
| Unique Identifier |
NASDAQ: XGN |
Description
Exagen Inc. operates as a commercial-stage diagnostics company, develops and markets products for the diagnosis, prognosis, and monitoring of patients affected by autoimmune rheumatic diseases (ARDs). Its lead product includes Avise SLE+CT, a proprietary diagnostic test that provides an enhanced solution for patients with a range of ARDs, such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjögren's syndrome, and scleroderma, as well as other disorders, including fibromyalgia. The company also offers Avise SLE Prognostic, a blood test that complements Avise SLE+CT; Avise MTX, a therapeutic drug monitoring test to measure levels of methotrexate polyglutamates; and Avise HCQ, a blood test for physicians to monitor blood levels of HCQ. In addition, it is developing Anti-TNF, a blood test to monitor the levels of anti-TNF bioactivity in patients with RA; Avise SLE Monitoring, a multi-analyte panel blood test for physicians to track the disease status of their SLE patients; and Avise RA, a blood test to determine bone damage or joint erosion. The company primarily serves rheumatologists in the United States. It was formerly known as Exagen Diagnostics, Inc. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.